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The epidermal growth factor receptor (EGFR) is aberrantly activat-
ed in a variety of epithelial cancers and has been the focus of much
interest as a therapeutic target in anti-cancer therapy. Here we
characterize the inhibition of EGFR dimerization and activation
by an antibody drug that is currently in phase I/II clinical trials. The
progress of our structural and biochemical studies is presented. We
compare our results with those known for the antibody cetuximab/
Erbitux, which is FDA approved for colorectal as well as head and
neck cancer since 2004. Both antibodies bind to domain III of the
receptor, but show different inhibitionmechanisms. The similarities
and differences of the two antibodies have important implications
for the development of new therapeutic approaches of EGFR
targeting.
3256-Pos Crystal Structure of the
Complex of Cameline Peptidoglycan
Recognition Protein with Disaccharide
at 3.2A

Resolution
Rishi Jain, Pradeep Sharma, Nagendra Singh, Sujata Sharma,
Punit Kaur, Tej Pal Singh
All India Institute of Medical Sciences, New Delhi, India.
Board B559
Peptidoglycan Recognition Protein (PGRP) is a soluble, conserved
pattern recognition protein of vertebrates and invertebrates that
binds to peptidoglycans (PGNs). PGNs form a group of conserved
microbial motifs (Pathogen - associated molecular patterns-
PAMPs) that are unique products of microbial metabolism not
produced by the host. PGNs are located on the surface of virtually
all bacteria and fungi and as such, constitute excellent targets to
recognition by PGRPs. We have isolated a 20 kDa PGRP from
cameline mammary secretions. It has been crystallized in the space
group I222 with cell dimensions, a = 89.9A

, b = 102.5 A

, c = 164.2 A

having 32 molecules in the unit cell. The structure reveals the
presence of two crystallographically independent dimers unlike
human PGRP, which is a monomer. PGN binding groove is located
in the domain close to C-terminus. Themolecular structure contains
a central b-sheet composed of five b-strands, four parallel and one
(b5) antiparallel and three a-helices. PGN binding site resides in a
long cleft whosewalls are formed by helix a1 and five loops b3 - a1,
a1- b4, b5- b6, b6 - a2 , b7 - a3. The second site is located on the
opposite side of the proteins to the PGN-binding site, which
apparently accommodates host effector or signaling molecules. It
is formed by variable PGRP-specific segment and helix a2. Dis-
accaride is observed in the Ligand binding cleft and interacts with
residues such as Glu 52, Asn 55 and Thr 38 of the A molecule.
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The role of cyclooxygenase2 (COX2) enzyme in cancer promotion
has been discovered almost a decade back. But the novelmechanism
by which lipoxygenase (LOX) enzyme and its products are co-
promoting the COX2 in cancer cell proliferation is now raising a
new question. Will the dual inhibition of COX2 and LOX enzymes
block the cancerous proliferation of cells and if so to what extent?
Preliminary studies done on this novel mechanism of cancer pre-
vention by inhibiting COX2/5LOX have shown excellent positive
results.
Keeping this in mind, we have used the available X-ray crystal
structures of the complexes of COX2 and LOX with the known
inhibitors to carry out a structure-based, rational, molecular model-
ing approach to design a small peptide inhibitor, which is potent for
both COX and LOX. Since the crystal structure of 5LOX is not
known, and since the active sites of human 5LOX and mammalian
15LOX are highly similar, the crystal structure of rabbit 15LOX
enzyme has been used. Docking studies using Discovery Studio 1.7
(Accelrys Software Inc) indicate that the designed peptide inhibits
both 15LOXandCOX2with potency in the nanomolar range, which
is about 1000 timesmore than the known dual LOX/COX inhibitors.
Furthermore, this designed inhibitor also blocks the COX1 enzyme
so that the unwanted cardiovascular side effects of COX2 selective
inhibitors are avoided. Thus, the designed small peptide inhibitor is
a novel lead compound for the design of a new class of anti-cancer
drugs.
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Finding novel antibiotics to combat the rise of drug resistance in
harmful bacteria is of enormous importance for human health.
Computational drug design is an emerging field that is concerned
with aiding synthetic chemists in this search for new potent in-
hibitors. In recent years, molecular dynamics based free energy
calculations have emerged as a useful tool to accurately calculate
binding affinities of novel or modified ligands. While being signifi-
cantly more demanding in computational resources than simpler
docking algorithms, they can be employed to obtain reliable esti-
mates of the effect individual functional groups have on protein-
ligand complex binding constants.
In this work, we analyze the effect of several chemical modifica-
tions on the binding of the natural inhibitor thiolactomycin to beta-
ketoacyl [acyl carrier protein] synthase I from E. coli . KAS I
facilitates a critical chain elongation step in the fatty acid synthesis
pathway. Since the bacterial type II lipid synthesis system is
fundamentally different from the mammalian type I multi-enzyme
complex, it represents a promising target for the design of specific
antibiotics.
We employed thermodynamic integration calculations to predict
the effect of changing functional groups on the thiolactomycin
scaffold. The Amber9 molecular dynamics suite, with additonal
modification to improve phase space sampling in free energy
calculations,was used for calculations. Several ligandmodifications
were found that could lead to thiolactomycin derivatives with
improved binding constants in the nanomolar range. When the six
most promising new compounds were synthesized and screened for
activity, they strongly inhibited bacterial growth.
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MDock is a suite of molecular docking program targeting single or
multiple protein structures. Efficient docking of a ligand against
multiple protein structures is an extremely useful tool for inclusion
of protein flexibility in ligand binding, prediction of ligand speci-
ficity, and rapid identification of inhibitors for a family of proteins.
The MDock program integrates the sphere-ligand matching algo-
rithm of UCSF DOCK (Ewing and Kuntz, J Comput Chem 18,
1175–1189, 1997), the ITScore energy scoring function (S.-Y.
Huang and X. Zou, J Comput Chem 27, 1866–1875; 1876–1882,
2006), and the Ensemble Docking algorithm (S.-Y. Huang and X.
Zou, Proteins 67, 399–421, 2007). MDock can simultaneously dock
a ligand into the userdefined binding site of the multiple protein
structures with little additional computational demand. The soft-
ware accounts for protein flexibility in ligand binding by using an
ensemble of multiple crystal structures or NMR conformers of the
same protein (S.-Y. Huang andX. Zou, Protein Sci 16, 43-51, 2007).
Here, MDock was tested on rapid identification of inhibitors for a
family of homologous proteins by simultaneous virtual database
screening against an ensemble of 18 protein kinases. The obtained
enrichments were shown to be comparable to those from the
standard single-target docking protocol for the individual kinase
protein. MDock was also applied to study ligand selectivity against
different target proteins by testing seven typical protein kinase
inhibitors against the above protein kinases. MDock is computa-
tionally efficient, and the run time is almost independent of the
number of protein structures and on average consumes ~ 2s on a
single 3.2 GHz Pentium IV CPU for docking one ligand conformer.
MDock can be obtained free of charge for academic users.
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It is estimated that one in eightAmericanwomenwill develop breast
cancer in her lifetime and a significant number of these cases are due
to misregulation of EGFR and ErbB2, two members of the epider-
mal growth factor receptor family (ErbB). In particular, 70–80% of
metaplastic breast carcinomas overexpress EGFR, and 30% of all
breast carcinomas overexpress ErbB2. Breast tumors overexpres-
sing one or both of these receptors are associated with aggressive
clinical malignancy. Current drugs based on large antibodies (mAb)
and tyrosine kinase inhibitors (TKIs) show promising yet highly
variable clinical efficacy. In addition, serious side-effects like
cardiotoxicity and comprised immune system further restricts their
clinical effectiveness. Recent advancements in the regulation of
ErbB-signaling suggest that these therapeutic limitations are due to
the underestimation of a muchmore complex system - a system that
relies on inter-receptor interactions through the process of homo-
and hetero- dimerization. These new findings therefore motivate the
development of novel inhibitors that target these receptor-receptor
interactions. The objective of this project is to identify the first class
of small-molecule inhibitors that target and disrupt the dimerization.
We are applying a cost- and time- effective protocol that combines in
silico virtual high-throughput screen (vHTS) and in vitro experi-
mental assays to identify lead compounds. Our approach contrasts
the traditional strategies of developing mAb- and TKI-based in-
hibitors. The application of computational methods provides a
realistic way to screen and test thousands of compounds. We have
experimentally tested top compounds predicted by the vHTS and
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have identified several candidate inhibitors with promising potency
and specificity in living cells. Our findings can serve as a building
block that carries promises for clinical benefit in treating ErbB-
driven breast cancers.
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Inhibition of the human cytoplasmic protein tyrosine phosphatase
(HCPTP) provides a mechanism by which to down regulate the
metastatic phenotype present in human epithelial tumors caused by
the underphosphorylation of the EphA2 receptor tyrosine kinase.
Inhibitors for each isoform of HCPTP have been identified by in
silico screening of small molecule libraries as well as through
rational design. In vitro kinetic analysis has verified the discovery
of low micro-molar inhibitors of HCPTP, which are the most potent
inhibitors of HCPTP reported to date. Common structural elements
have been identified among these strong inhibitors that agree with
rationally designed elements. Structural information of inhibitors
bound to the enzyme is now necessary. Crystal structures of both
isoforms of HCPTP have been generated within the laboratory and
crystallographic analysis of inhibitor-enzyme complexes can now
proceed. Additional enzymatic analysis of mutants of HCPTP will
be performed in order to elucidate the roles of individual amino
acids that line the entrance of the active site of each isoform of
HCPTP in the binding to inhibitors. Comparison of efficiency of
inhibitors at several pHs will aid in the elucidation of physiological
roles for each isoform of HCPTP. Each of these results will direct
inhibitor development as well as elucidate the future of isoform-
specific inhibitors of HCPTP.
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Self-assembly of peptides is a recurring theme in research and one of
the most important strategies used in wide range of applications in
biotechnology andmaterial sciences. Indeed, a better understanding
and control of the hierarchical structure formation should drive us to
a better knowledge of biological processes in general. This in turn
will lead us to new conceptions of biomimetic nanomaterials.
We areworking on Lanreotide, a synthetic analogue of the natural
Somatostatin. The lanreotide, an octapeptide, self-assembles into
well defined hierarchical structures. Currently, Lanreotide acetate is
used as a therapeutic peptide in the treatment of acromegaly in the
form of a gel at high concentrations (3–30%w/v). The self-assem-
bling into nano-tubes of Lanreotide acetate in water strongly
suggests a correlation between Lanreotide nano-organization and
the controlled release properties of this pharmaceutical product
during medical treatment. Here we chose a multidisciplinary ap-
proach to study lanreotide and its derivatives, by combining polar-
ized light microscopy, electron microscopy, vibrational spectro-
scopies, small and wide angle X-ray scattering, and analytical ultra
centrifugation to elucidate:
(i) -the hierarchical structures formed and
(ii) -themolecular and supramolecular self-assemblymechanism.
We have recently shown the self-assembly occurs through the
association of b-sheets driven by amphiphilicity and a systematic
aromatic/aliphatic side chain segregation. The assembly is the result
of a fine equilibrium between:
(i) -ionic strength,
(ii) -hydrophobic effect and
(iii) -H-bond network.
As a result we are able to govern the morphology of the object
formed: fibres, ribbons and nanotubes with specific diameter. This
original and simple system is a unique example of molecules able to
self-organize into a well-defined nanostucture. The supramolecular
organization of Lanreotide and derivatives demonstrates that this
system is able to investigate the minimal interactions required for
generating large self-assembling nanoscale structures, including
proteins and could find implications for b-amyloid fibers.
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Modern, highly sensitive Isothermal Titration Calorimetry (ITC)
instruments are being applied in the drug discovery and develop-
ment process for applications such as selection of small molecule
“hits” following primary and secondary screening of chemical
libraries against protein targets of interest, optimization of small
molecule leads based on elucidation of the binding mechanism and
binding characteristics and development of structure-activity-rela-
tionships (SAR) that are used in the optimization process, and
selection and optimization of therapeutic protein variants. As
modern ITC instrumentation has evolved, these instruments have
becomemore sensitive, faster and easier to use. Binding parameters
determined by ITC are often referred to as the “gold standard”
values and are frequently used as reference standard values for other
techniques. Despite the fundamental advantages of this technique
and the advances in instrumentation, use of ITC in the early, critical
decision-making stages of drug discovery is often limited due to the
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lack of sufficient quantities of protein during those early stages and
the time required to perform the ITC experiments on large numbers
of potential ligands (or protein constructs) of interest. Traditionally
50 -1500 mg of protein has been consumed to complete an ITC
experiment and completing each experiment could require two
hours or more. Data presented we will describe the characteristics
of a new miniaturized, ultrasensitive ITC that has been designed to
push back these limitations allowing ITC to be effectively utilized at
earlier stages of the drug discovery and development process.
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Human cathelicidine hCAP18 is a potential lead structure for new
antibiotics to overcome the rising number of pathogenic multidrug
resistant bacterial strains.
In the case of Gram-negative bacteria, the first contact sites of
antimicrobial peptides are the molecules of the outer leaflet of the
outer membrane, mainly Lipopolysaccharide (LPS). LPS is able to
induce an inflammatory response, which may cause the fatal septic
shock.
To investigate the structure-activity relationship between LL-32,
an active fragment of hCAP18, and LPS, especially the influence of
the core oligosaccharides, we used fragments of LL-32, lacking
some amino acids residues, and Salmonella enterica serovar Min-
nesota strains differing in the length and charge of the core oligo-
saccharides. In vivo hCAP18 is processed to even shorter peptides
than LL-32, so these fragments might play an important role in the
immune system.
We determined the antibacterial and antiinflammatory activities
of these peptides against the S. enterica strains. Furthermore, we
measure the interaction of the fragments with membrane-models
composed of different LPS with physical methods. Binding of LL-
32 to LPS and bacteria was investigated by ITC and by measuring
the Zeta-potential. After binding to LPS, LL-32 induce lesions or
disrupt the membrane by micellisation. We measured the ability of
the fragments to fuse LPS-aggregates using a spectroscopic assay
based on F€orster Resonance Energy Transfer. Furthermore, we
determined the size of LPS-aggregates in dependence of the LL-
32 concentration. FACSmeasurements using fluorescently-labelled
LL-32 on bacteria showed that LL-32 bind instantly to bacteria
leading to a permeabilisation of the membranes.
Our data allows to explain the different biological activities of
LL-32 by means of biophysical data. Furthermore, the different
behaviour of the used fragments allows identifying specific residues
in the AA sequence of LL-32, which are important for its activities.
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Flexible sequence-random polymers containing cationic and lipo-
philic subunits, which can be induced by a bacterial membrane
surface to adopt globally amphiphilic irregular structures, have been
synthesized (Mowery, B.P., et al., submitted for publication). These
polymers are mimics of antimicrobial host-defence peptides, which
act by disrupting bacterial membranes. We have studied one such
copolymer, BPM2-39B, having an average length of 21 residues,
which is very active against both Gram positive and Gram negative
bacteria, with regard to its ability to disrupt model and bacterial
membranes. Our findings show that at very low concentrations,
comparable to their MIC values, it is able to permeabilize, in a
highly cooperative fashion, model membranes mimicking the lipid
composition of E. coli, S. aureus and B. subtilis. It is ineffective
against zwitterionic membranes, which explains its low hemolytic
capacity. Both DSC and ITC indicate that it is capable of binding as
well as segregating anionic lipids, forming anionic lipid-rich and
anionic lipid-poor domains. Experiments with the E. coli mutant
ML-35p, indicated that permeabilization in Gram negative bacteria
is biphasic; at low concentrations (up to 25 mg/mL) the polymer is
capable of permeabilizing the outer membrane, which is blocked at
higher concentrations of polymer. Experiments with E. coli K-12,
showed that at very low concentrations the polymer is also able to
reach and disrupt the inner cytoplasmic membrane. Despite the fact
that at higher concentrations the polymer does not permeate the
innermembrane, it associates with the negatively chargedLPS layer
(or LTA in gram positive bacteria), with lethal consequences for the
organism.We propose then a dual mechanism of bacterial killing by
flexible sequence-random copolymers, which differ at low and high
concentrations of polymer.
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DNA architecture plays a key role in determining spatial and
temporal patterns of gene expression. This architecture encom-
passes both the nucleotide sequence (i.e., the information content)
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